Capricor Therapeutics Inc (CAPR)

NASDAQ
5.760
+0.040(+0.70%)
After Hours
5.800
+0.040(+0.694%)
- Real-time Data
  • Volume:
    106,597
  • Day's Range:
    5.560 - 5.970
  • 52 wk Range:
    2.560 - 6.202

CAPR Overview

Prev. Close
5.72
Day's Range
5.56-5.97
Revenue
204K
Open
5.58
52 wk Range
2.56-6.202
EPS
-1.05
Volume
106,597
Market Cap
140.23M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
181,157
P/E Ratio
-5.49
Beta
4.87
1-Year Change
10.13%
Shares Outstanding
24,346,233
Next Earnings Date
Nov 09, 2022
What is your sentiment on Capricor Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Capricor Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Capricor Therapeutics Inc Analysis

Capricor Therapeutics Inc Company Profile

Capricor Therapeutics Inc Company Profile

Employees
48

Capricor Therapeutics, Inc. is a biotechnology company that is focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. The Company consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The Company is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

Read More

Analyst Price Target

Average15.000 (+160.42% Upside)
High18
Low12
Price5.76
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Buy
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Buy
  • The clinical trials news seemed good, but the stock got hit hard. Any ideas for today? Thanks.
    0
    • $10, $Capr has Cap $60M, Contract $705M, Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million.
      0
      • nevermind
        1
        • buy
          1
          • should buy?
            1
            • This is a company that leaves investors without any news or updates. Linda mentions FDA approval "Soon" which is years. Linda was mentioning about her Cap 1002 for the past years and repeats the same garbage over and over. They are not doing nothing.
              1
          • Does anyone know when the clinical news is supposed to be released?
            0
            • Will be some news tomorrow afternoon at 4.30
              0
          • Where do we go from here?
            0
            • Up up and away!!!! Gonna be a fun couple of weeks
              0
            • down and under !
              0
          • where is CAPR headed?
            0
            • prediction for eom?
              0
              • it should go to 12-14 by August 2nd week.
                1
                • still ???
                  0